de Bruijn, A.; Schipper, R.-J.; Voogd, A.C.; Pullens, M.J.J.; Bloemen, J.G.; de Munck, L.; van Riet, Y.E.; Siesling, S.; Vriens, B.E.P.; Nieuwenhuijzen, G.A.P.
Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study. Cancers 2024, 16, 4188.
https://doi.org/10.3390/cancers16244188
AMA Style
de Bruijn A, Schipper R-J, Voogd AC, Pullens MJJ, Bloemen JG, de Munck L, van Riet YE, Siesling S, Vriens BEP, Nieuwenhuijzen GAP.
Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study. Cancers. 2024; 16(24):4188.
https://doi.org/10.3390/cancers16244188
Chicago/Turabian Style
de Bruijn, Anne, Robert-Jan Schipper, Adri C. Voogd, Marleen J. J. Pullens, Johanne G. Bloemen, Linda de Munck, Yvonne E. van Riet, Sabine Siesling, Birgit E. P. Vriens, and Grard A. P. Nieuwenhuijzen.
2024. "Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study" Cancers 16, no. 24: 4188.
https://doi.org/10.3390/cancers16244188
APA Style
de Bruijn, A., Schipper, R.-J., Voogd, A. C., Pullens, M. J. J., Bloemen, J. G., de Munck, L., van Riet, Y. E., Siesling, S., Vriens, B. E. P., & Nieuwenhuijzen, G. A. P.
(2024). Adding Anti-HER2 Therapy to Neoadjuvant Endocrine Therapy Seems Effective in Hormone Receptor and HER2 Positive Breast Cancer Patients Unfit for Chemotherapy: A Nationwide Population-Based Cohort Study. Cancers, 16(24), 4188.
https://doi.org/10.3390/cancers16244188
